These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 35178186)
21. Identification of novel PDEδ interacting proteins. Küchler P; Zimmermann G; Winzker M; Janning P; Waldmann H; Ziegler S Bioorg Med Chem; 2018 May; 26(8):1426-1434. PubMed ID: 28935183 [TBL] [Abstract][Full Text] [Related]
22. Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction. Chen D; Chen Y; Lian F; Chen L; Li Y; Cao D; Wang X; Chen L; Li J; Meng T; Huang M; Geng M; Shen J; Zhang N; Xiong B Eur J Med Chem; 2019 Feb; 163():597-609. PubMed ID: 30562696 [TBL] [Abstract][Full Text] [Related]
23. Molecular mechanism of the association and dissociation of Deltarasin from the heterodimeric KRas4B-PDEδ complex. Bello M; Correa-Basurto J; Vargas-Mejía MÁ Biopolymers; 2019 Nov; 110(11):e23333. PubMed ID: 31568570 [TBL] [Abstract][Full Text] [Related]
24. Discovery of Turn-On Fluorescent Probes for Detecting PDEδ Protein in Living Cells and Tumor Slices. Dong G; Chen L; Zhang J; Liu T; Du L; Sheng C; Li M Anal Chem; 2020 Jul; 92(14):9516-9522. PubMed ID: 32571022 [TBL] [Abstract][Full Text] [Related]
25. Dissociation of the K-Ras4B/PDEδ complex upon contact with lipid membranes: membrane delivery instead of extraction. Weise K; Kapoor S; Werkmüller A; Möbitz S; Zimmermann G; Triola G; Waldmann H; Winter R J Am Chem Soc; 2012 Jul; 134(28):11503-10. PubMed ID: 22721555 [TBL] [Abstract][Full Text] [Related]
26. Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation. Go A; Jang JW; Lee W; Ha JD; Kim HJ; Nam HJ Eur J Med Chem; 2020 Oct; 204():112635. PubMed ID: 32726747 [TBL] [Abstract][Full Text] [Related]
27. Membrane protein transport in photoreceptors: the function of PDEδ: the Proctor lecture. Baehr W Invest Ophthalmol Vis Sci; 2014 Dec; 55(12):8653-66. PubMed ID: 25550383 [TBL] [Abstract][Full Text] [Related]
28. LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer. Qiu J; Bai X; Zhang W; Ma M; Wang W; Liang Y; Wang H; Tian J; Yu P Front Pharmacol; 2022; 13():853993. PubMed ID: 35479314 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity. Leung ELH; Luo LX; Liu ZQ; Wong VKW; Lu LL; Xie Y; Zhang N; Qu YQ; Fan XX; Li Y; Huang M; Xiao DK; Huang J; Zhou YL; He JX; Ding J; Yao XJ; Ward DC; Liu L Cell Death Dis; 2018 Feb; 9(2):216. PubMed ID: 29440631 [TBL] [Abstract][Full Text] [Related]
30. Photoreceptor cGMP phosphodiesterase delta subunit (PDEdelta) functions as a prenyl-binding protein. Zhang H; Liu XH; Zhang K; Chen CK; Frederick JM; Prestwich GD; Baehr W J Biol Chem; 2004 Jan; 279(1):407-13. PubMed ID: 14561760 [TBL] [Abstract][Full Text] [Related]
31. Assay and functional properties of PrBP(PDEdelta), a prenyl-binding protein interacting with multiple partners. Zhang H; Hosier S; Terew JM; Zhang K; Cote RH; Baehr W Methods Enzymol; 2005; 403():42-56. PubMed ID: 16473576 [TBL] [Abstract][Full Text] [Related]
32. The interplay between RPGR, PDEδ and Arl2/3 regulate the ciliary targeting of farnesylated cargo. Wätzlich D; Vetter I; Gotthardt K; Miertzschke M; Chen YX; Wittinghofer A; Ismail S EMBO Rep; 2013 May; 14(5):465-72. PubMed ID: 23559067 [TBL] [Abstract][Full Text] [Related]
33. The KRAS-PDEδ interaction is a therapeutic target. Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364 [TBL] [Abstract][Full Text] [Related]
34. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Chandra A; Grecco HE; Pisupati V; Perera D; Cassidy L; Skoulidis F; Ismail SA; Hedberg C; Hanzal-Bayer M; Venkitaraman AR; Wittinghofer A; Bastiaens PI Nat Cell Biol; 2011 Dec; 14(2):148-58. PubMed ID: 22179043 [TBL] [Abstract][Full Text] [Related]
35. Expression and characterization of human PDEdelta and its Caenorhabditis elegans ortholog CEdelta. Li N; Baehr W FEBS Lett; 1998 Dec; 440(3):454-7. PubMed ID: 9872421 [TBL] [Abstract][Full Text] [Related]
36. Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy. Shi S; Du Y; Huang L; Cui J; Niu J; Xu Y; Zhu Q Bioorg Chem; 2022 Mar; 120():105605. PubMed ID: 35081479 [TBL] [Abstract][Full Text] [Related]
37. Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor. Kato JY; Korenaga S; Iwakura M Bioorg Med Chem Lett; 2023 Jan; 79():129083. PubMed ID: 36414177 [TBL] [Abstract][Full Text] [Related]
38. Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type Wang X; Yamamoto Y; Imanishi M; Zhang X; Sato M; Sugaya A; Hirose M; Endo S; Natori Y; Moriwaki T; Yamato K; Hyodo I Oncol Lett; 2021 Jul; 22(1):558. PubMed ID: 34084225 [TBL] [Abstract][Full Text] [Related]
39. Mapping the isoprenoid binding pocket of PDEdelta by a semisynthetic, photoactivatable N-Ras lipoprotein. Alexander M; Gerauer M; Pechlivanis M; Popkirova B; Dvorsky R; Brunsveld L; Waldmann H; Kuhlmann J Chembiochem; 2009 Jan; 10(1):98-108. PubMed ID: 18846587 [TBL] [Abstract][Full Text] [Related]
40. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. Zhou C; Fan Z; Zhou Z; Li Y; Cui R; Liu C; Zhou G; Diao X; Jiang H; Zheng M; Zhang S; Xu T J Med Chem; 2022 Mar; 65(5):3923-3942. PubMed ID: 35230841 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]